C-reactive protein is a potential prognostic factor for metastatic gastric cancer

Anticancer Research

Volumn 32, Issue 2, 2012, Pages 491-496

  Shimura, Takaya ^a   Kitagawa, Mika ^a   Yamada, Tomonori ^b   Ebi, Masahide ^a   Mizoshita, Tsutomu ^a   Tanida, Satoshi ^a   Kataoka, Hiromi ^a   Kamiya, Takeshi ^a   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

C reactive protein; CDDP; Chemotherapy; Gastric cancer; Prognostic factor; S 1

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN; FLUOROPYRIMIDINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HEARING IMPAIRMENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXONIC ACID; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 84856824682     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. International Agency for Research on Cancer GLOBOCAN 2008. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 (last accessed on December 18, 2011).
2. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006.
3. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I and Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28: 1547-1553, 2010.
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
5. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
6. Grimm RH, Jr., Neaton JD and Ludwig W: Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. JAMA 254: 1932-1937, 1985.
7. Erlinger TP, Platz EA, Rifai N and Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590, 2004.
8. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Kedra B, Lukaszewicz M, Baniukiewicz A and Szmitkowski M: Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 46: 1423-1428, 2008.
9. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y and Onitsuka T: Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 27: 3001-3004, 2007.
10. Lukaszewicz-Zajac M, Mroczko B, Gryko M, Kedra B and Szmitkowski M: Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 11: 89-96, 2011.
11. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, Kim SG, Kim SH, Jang JS, Kim MC, Kim KH, Han JY and Kim HJ: Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9: 155, 2009.
12. Ilhan N, Ilhan Y, Akbulut H and Kucuksu M: C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 10: 1115-1120, 2004.
13. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A and Sudo A: Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer: Jul 14 (Epub ahead of print), 2011.
14. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J and Mucci LA: Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 124: 2683-2689, 2009.
15. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A and Ulrich CM: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444, 2009.
16. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J and Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241-1247, 2007.
17. McMillan DC, Canna K and McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215-219, 2003.
18. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS and Milroy R: The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable nonsmall cell lung cancer. Br J Cancer 87: 264-267, 2002.
19. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF and Commes T: C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31: 351-357, 1998.
20. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ and Carter DC: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75: 2077-2082, 1995.
21. Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A and Ezaki T: Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg 201: 186-191, 2011.
22. Nozoe T, Iguchi T, Adachi E, Matsukuma A and Ezaki T: Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today 41: 510-513, 2011.
23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
25. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. http://evs.nci.nih.gov/ftpl/CTCAE/. (last accessed on December 18, 2011).
26. Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS and Kang YK: Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 37: 30-37, 2007.
27. Chau I, Norman AR, Cunningham D, Waters JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22: 2395-2403, 2004.
28. Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L and Inferrera C: Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol 15: 831-837, 2002.
29. Maguire A, Porta M, Sanz-Anquela JM, Ruano I, Malats N and Pinol JL: Sex as a prognostic factor in gastric cancer. Eur J Cancer 32A: 1303-1309, 1996.